News for XOMA Corporation (XOMA)

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as Gen

EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ( XOMA), the biotech royalty aggregator, and BioInvent Internat

**media[637970,637971]**

XOMA Royalty Corporation (NASDAQ: XOMA) will participate in two key investor conferences in May 2025. CEO Owen Hughes and CIO Brad Sitko will lead discu

Benchmark analyst Robert Wasserman has commenced coverage of Xoma Corporation (XOMA), assigning a Buy rating and setting a price target of $35. The analyst high

XOMA Royalty (XOMA) completes sale of five Kinnate pipeline assets for up to $270 million. The transaction includes upfront, milestone payments, and roy

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where XOMA Royalty Corporation (NASDAQ:XOMA) stands against other stocks that insiders bought in April after Trump’s tariff rollout. President Donald Trump called April 2 a “Liberation Day” after […]

XOMA's preferred shares (XOMAO, XOMAP) offer secure, attractive yields backed by biotech royalties, FDA-approved assets, and strategic growth. See more here.

**media[583713]**

**media[568943]**

**media[531606]**

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk profile may not suit all investors.

Xoma Royalty's chief investment officer buys $13,974 in stock

**media[509408]**

XOMA Corporation (XOMA) experienced a significant stock movement, with its price rising by 5.45% to $32.70 per share. The trading volume reached 32,220 shares,

Genomics is the study of genes and how they function.

Twist Biosciences has a solid balance sheet but continues to face losses. Read why TWST stock may be hard to value despite its recent Q4 performance.

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?